CSL Limited (CSL.AX) Stock

CSL.AX logo

CSL Limited

CSL.AXAustralia
Healthcare

Company profile

CSL reported revenue of $15.70 billion for fiscal year 2026, up 1.7% from fiscal year 2025. Its largest business segment, CSL Behring, brought in 72% of segment revenue in fiscal year 2026; United States was the largest region with 47%. Our analysis of its filings shows revenue growing from $14.69 billion in fiscal year 2024 to $15.70 billion in fiscal year 2026, 3.4% a year on average. CSL reports about 29,000 full-time employees.

What stands out

  • It reported a net loss of $2.58 billion in fiscal year 2026, after a profit of $3.00 billion in fiscal year 2025.
  • Revenue in fiscal year 2026 was the highest of the last 5 fiscal years.
  • It was founded in 1916.

Figures from company filings; latest fiscal year ended June 30, 2026.

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Largest shareholders

  • BlackRock Fund Advisors3.56%
  • BlackRock Investment Management (Australia) Ltd.1.19%
  • State Street Global Advisors Trust Co.1.09%
  • BlackRock Investment Management (UK) Ltd.0.95%
  • Netwealth Investments Ltd.0.87%

Share of the company, as of September 25, 2026

Leadership

  • Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A. — CEO, MD & Executive Director, 62
  • Ken Lim — Chief Financial Officer, 51
  • Mary Oates Ph.D. — Executive VP & COO, 62
  • Amy Van Buren — Chief People Officer, 50
  • William Mezzanotte M.D., M.P.H. — Chief Medical Officer, Executive VP and Head of Research & Development, 66

How much revenue does CSL make?

CSL reported $15.70 billion in revenue for fiscal year 2026, up 1.7% from $15.43 billion in fiscal year 2025.

What is CSL's largest business segment?

CSL Behring, with $11.39 billion or 72% of segment revenue in fiscal year 2026. Next: Csl Vifor (15%) and CSL Seqirus (13%).

Where does CSL make most of its revenue?

United States: 47% of revenue by region in fiscal year 2026, followed by Rest of World (31%).

What companies are similar to CSL?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Mayne Pharma Group Limited (MYX.AX), BTC Health Limited (BTC.AX), Acrux Limited (ACR.AX), Argent BioPharma Limited (RGT.AX).

Has CSL made a profit in recent years?

Net income by fiscal year: FY2022, $2.25 billion; FY2023, $2.19 billion; FY2024, $2.64 billion; FY2025, $3.00 billion; FY2026, a loss of $2.58 billion. It reported a net loss in 1 of these 5 years.

How has CSL's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2022, $10.49 billion; FY2023, $13.17 billion; FY2024, $14.69 billion; FY2025, $15.43 billion; FY2026, $15.70 billion.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees29,000
FoundedJan 1, 1916
IPO DateJun 3, 1994
IPO StatusPublic
HeadquartersMelbourne, Australia
ExchangeASX
TimezoneAustralia/Sydney (AEDT)

Contact & Links

Address
655 Elizabeth Street, Melbourne, 3000
Phone
61 3 9389 1911
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “CSL Limited (CSL.AX)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/CSL.AX

LinkedInLinkedInXXYouTubeYouTube